--- title: Wegovy vs Mounjaro Side Effects Comparison 2026 – Pepio Guide date: '2026-07-22' slug: wegovy-vs-mounjaro-side-effects-comparison-2026-pepio-guide description: Compare Wegovy and Mounjaro side effects in 2026, see key differences, and learn how Pepio’s GLP‑1 tracker helps you log symptoms and discuss with your clinician. updated: '2026-07-22' image: https://images.unsplash.com/photo-1765445666248-7e06454687e8?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=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&ixlib=rb-4.1.0&q=80&w=400 author: Dr. Benjamin Paul site: 'Pepio: GLP-1 Peptide Tracker' --- # Wegovy vs Mounjaro Side Effects Comparison 2026 – Pepio Guide ## Why Compare Wegovy and Mounjaro Side Effects in 2026? This guide compares Wegovy vs Mounjaro side effects and explains why tolerability matters for people on GLP‑1 therapies. Wegovy (semaglutide) is approved for chronic weight management, and Mounjaro (tirzepatide) is approved for type 2 diabetes (with Zepbound as tirzepatide’s weight‑management counterpart). Side effects influence whether you stick with therapy and how you plan follow‑up care. Clinical summaries show higher nausea with Wegovy (~30%) than with Mounjaro (~25%) ([Drugs.com comparative analysis](https://www.drugs.com/medical-answers/mounjaro-wegovy-ozempic-compare-weight-loss-3570898/)). Severe gastrointestinal events were also reported more often with Wegovy in trial data. Recent analyses note a slightly higher rate of mild hypoglycemia with Mounjaro (~5%) versus Wegovy (~2%) as broader populations use these medicines ([A Personal Physician side-effect comparison (2026)](https://apersonalphysician.com/blog/ozempic-wegovy-and-other-glp-1-medications-benefits-side-effects-and-realistic-expectations)). These differences are modest but useful when setting expectations and tracking symptoms. Pepio helps you record symptoms, injection sites, and weight changes so you can see patterns over time. People using Pepio keep clearer side‑effect timelines for clinician visits. Pepio’s approach to routine organization makes it easier to monitor tolerability without relying on memory. Use Pepio to track side effects across either therapy. Pepio is for organization and self‑tracking only; follow your prescriber’s instructions. ## How to Evaluate GLP‑1 Medication Side Effects If you’re searching for *how to evaluate GLP‑1 medication side effects*, use a simple rubric to compare profiles and plan monitoring. Call it the **Side‑Effect Evaluation Framework**. This framework helps you decide what to watch and when to ask for help. - How common and how bad - Frequency — percentage of users reporting the effect. This sets expectations for how common a symptom may be. - Severity — mild, moderate, severe classifications. Severity helps you judge whether symptoms need clinical attention. - When it happens - Onset timing — early (first days) vs later in the treatment cycle. Knowing onset timing guides when to monitor closely. - Duration — transient vs persistent. Duration tells you whether a symptom will likely resolve after titration. - Impact on daily life - User‑impact — effect on work, exercise, sleep, and appetite. User‑impact measures how much daily life the side effect disrupts. Use clinical trial data and real‑world reports together when you apply this framework. Gastrointestinal symptoms occur in about 20–30% of GLP‑1 users, so frequency is a key comparison point ([Journal of Clinical Investigation](https://www.jci.org/articles/view/194740)). Onset often happens within the first week, and many cases resolve within 2–4 weeks after dose adjustments, according to the same review ([Journal of Clinical Investigation](https://www.jci.org/articles/view/194740)). Manufacturer labels, such as the Wegovy prescribing information, add detail on reported side effects and their timing for specific medications ([FDA Wegovy label (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s015lbl.pdf)). Compare medications side‑by‑side using these five criteria for a clear view of trade‑offs. Track symptoms consistently and record timing and severity so you can spot patterns between doses. Pepio helps people keep those records in one place, so symptom timelines and dose history are easier to review. Users of Pepio report clearer notes for follow‑ups and less guesswork about when side effects started. Learn more about Pepio’s approach to routine tracking if you want an organized way to apply the Side‑Effect Evaluation Framework before your next clinician visit. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, or treatment. Always follow instructions from your clinician, prescriber, pharmacist, or medication label. ## Pepio GLP‑1 Tracker – Your Side‑Effect Logging Solution Pepio helps you log each GLP‑1 injection, symptom, and injection site with a timestamp, then turns those entries into a clear timeline you can review. This practical record makes it easier to spot weekly patterns and trends in dose changes ([Pepio: GLP‑1 Peptide Tracker](https://pepio.app)). Pepio’s web tools are free, require no sign‑up, and store data locally on your device. Web tools offer downloadable calendar reminders, and the iOS app adds push notifications for next doses, persistent history, site‑rotation memory, weight and symptom trend charts, and PDF export. Separate research shows symptom‑tracking apps increase patient‑reported side effects by about 22% compared with calendar apps, showing the value of a dedicated tracker for capturing real experience ([Effect of Symptom‑Tracking Apps on Reporting (PubMed)](https://pubmed.ncbi.nlm.nih.gov/32790051/)). - Symptom logging — you can record nausea, constipation, fatigue, appetite changes, and food noise with timing and severity for each entry. - Automatic timeline view — the timeline shows how symptoms and injections line up so you can see trends over days and weeks. - Reminder integration — set reminders or enable push notifications to help reduce missed doses and missed entries. - Exportable reports — generate PDFs or exportable summaries to bring clear notes and timelines to your clinician. - Pepio’s free web calculators — use the calculators to keep vial and dose math separate from symptom tracking so your logs stay organized. Pepio maps cleanly to a simple evaluation framework every user needs. Frequency is captured by regular symptom logs and timeline density. Severity is recorded in symptom fields so you can compare mild and severe entries. Onset and duration appear directly on the timeline, showing how long side effects last after a shot. User impact is visible through notes and linked weight data, making the practical effects easier to discuss. For people comparing side‑effect trackers, Pepio’s approach focuses on making side‑effect data usable for real conversations. Users who use Pepio report clearer summaries and faster clinician reviews because reports and timelines are exportable and easy to share. Pepio’s free web calculators also let you handle vial and dose math separately from symptom notes, so tracking stays organized without mixing clinical decisions into your logs ([Pepio: GLP‑1 Peptide Tracker](https://pepio.app)). The privacy‑first, no‑sign‑up web tools keep your data local, while the iOS app offers push notifications and PDF export when you want persistent history and shareable reports. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, dosing recommendations, or protocol recommendations. Always follow the instructions from your clinician, prescriber, pharmacist, medication label, or care team. Learn more about Pepio’s approach to side‑effect tracking and how it can simplify your GLP‑1 routine. ## Wegovy Side‑Effect Profile Wegovy’s most common adverse reactions are gastrointestinal, especially nausea, vomiting, diarrhea, and constipation. Clinical trials reported nausea in roughly 30–40% of participants, with similar GI rates for diarrhea and constipation ([FDA Wegovy Prescribing Information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf)). Real‑world summaries and trial compilations report comparable frequencies ([Drugs.com Wegovy Side‑Effects Summary (2024)](https://www.drugs.com/sfx/wegovy-side-effects.html)). GI symptoms most often appear early. Nausea and related effects typically begin within the first 2–4 weeks of treatment and tend to ease for many people over time ([Wegovy Official Safety & Side‑Effects Page (2024)](https://www.wegovy.com/obesity/is-wegovy-right-for-me/safety-side-effects.html)). Severe gastrointestinal events are uncommon but did occur in trial populations at about 4.1%, versus 0.9% for placebo ([FDA Wegovy Prescribing Information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf)). Tracking matters because persistent or worsening symptoms may require clinical review. Keep a concise record of timing, severity, and duration. Pepio helps you store that routine information so patterns are easier to spot and share with your clinician. People using Pepio report clearer symptom timelines and cleaner dose histories when preparing for follow‑up visits. Pepio’s approach to organizing shots, symptoms, and weight progress makes it simpler to notice persistent problems early. - Nausea — frequency, typical onset, patient tips. Track onset, severity, and whether it eases after dose weeks; logging helps your clinician assess timing. - Constipation — prevalence, duration, self‑care ideas. Note when constipation begins and how long it lasts; this clarifies whether patterns align with dose changes. - Diarrhea — occurrence rate, when it appears. Record timing and frequency to distinguish short‑term reactions from ongoing issues. - Headache — how often reported, impact on work. Log severity and work impact so you can mention functional effects during appointments. - Other — fatigue, injection site reactions. Capture less common effects to build a complete symptom picture over time. If you have severe or persistent symptoms, contact your clinician promptly. Learn more about Pepio’s approach to organizing GLP‑1 routines and symptom logs to make clinic conversations clearer. ## Mounjaro Side‑Effect Profile Mounjaro side effects overview 2026: tirzepatide commonly causes gastrointestinal effects, and users should track symptoms and timing to spot patterns. Clinical trials reported nausea, diarrhea, decreased appetite, vomiting, and constipation as the top events. For example, nausea occurred in 17% of participants at 15 mg in SURPASS‑2 versus 5% with placebo ([FDA Drug Trials Snapshots – Mounjaro](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-mounjaro)). Diarrhea rates reached about 13% in SURPASS‑3 compared with 4% for placebo ([FDA Drug Trials Snapshots – Mounjaro](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-mounjaro)). Beyond common GI events, rare but serious signals exist. Pooled safety data showed pancreatitis in roughly 0.3% of trial participants (5 cases in 7,769 patients), and gallbladder-related issues also appeared in safety reviews ([Mounjaro US Prescribing Information (USPI)](https://pi.lilly.com/us/mounjaro-uspi.pdf)). The USPI also notes rodent findings of thyroid C‑cell tumors, which led to a boxed warning; the human relevance remains uncertain but warrants awareness ([Mounjaro US Prescribing Information (USPI)](https://pi.lilly.com/us/mounjaro-uspi.pdf)). Real‑world pharmacovigilance since 2024 highlighted additional signals. Post‑marketing reports increased instances of GERD and dyspepsia among tirzepatide users, a pattern that may not appear in every trial but shows up in broader use ([Frontiers in Pharmacology, 2024](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1397029/full)). Mild hypoglycemia has been reported in some users, especially when combined with other glucose‑lowering agents; monitoring and clinician guidance matter ([Mounjaro US Prescribing Information (USPI)](https://pi.lilly.com/us/mounjaro-uspi.pdf)). Keeping a clear, dated record helps you notice recurring issues such as late‑night reflux or low‑blood‑sugar symptoms. Pepio helps users log dose dates, symptoms, and food‑noise changes so patterns are visible over weeks. Users tracking with Pepio can bring organized notes to clinicians, making follow‑up conversations more efficient. Pepio’s focus is on routine organization and self‑tracking, not medical advice. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, or dosing recommendations. Always follow your clinician, prescriber, pharmacist, or medication label, and contact a healthcare professional for concerning symptoms. In head‑to‑head data, nausea appears more common with Wegovy than with Mounjaro. Trial and label data show Wegovy nausea rates around 30–40% ([FDA Wegovy Prescribing Information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf)), while Mounjaro reports are generally lower, roughly 17–25% in published summaries ([Mounjaro US Prescribing Information](https://pi.lilly.com/us/mounjaro-uspi.pdf)). For a side‑by‑side overview, see the comparative analysis on [Drugs.com](https://www.drugs.com/medical-answers/mounjaro-wegovy-ozempic-compare-weight-loss-3570898/). Constipation and diarrhea rates vary between studies and between individuals. The overall incidence can be similar, but onset and duration often differ. Wegovy’s STEP trial results show earlier, more frequent nausea in the initial weeks ([FDA Wegovy Prescribing Information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf)). Mounjaro shows broader GI variability and additional reflux or GERD signals in some reports ([Mounjaro US Prescribing Information](https://pi.lilly.com/us/mounjaro-uspi.pdf)). These timing differences matter because early nausea may reduce appetite temporarily, while later or recurrent GI effects can disrupt routines or fluid intake. Track the details that let you spot patterns and share clear notes with your clinician. Pepio helps you keep those symptom windows organized so you can review trends over time. Users logging consistently with Pepio often find it easier to correlate symptoms with dose timing and weight changes. 1. Log timing — day of onset after injection (first week vs later). 2. Rate severity — mild/moderate/severe and note activity impact. 3. Record duration — how many days it lasted and whether it recurred. 4. Note related symptoms — vomiting, diarrhea, appetite loss, GERD, or hypoglycemia signs. 5. Track weight/appetite changes — correlate symptom windows with appetite or weight shifts. If symptoms are severe or you see warning signs, contact your clinician. Pepio is for organization and self‑tracking only and does not provide medical advice. Both Wegovy and Mounjaro commonly cause gastrointestinal side effects, but their frequency and timing can differ. Tracking doses and symptoms helps you see which effects you personally experience and when. Symptom‑tracking tools increase reporting and make patterns easier to spot ([Effect of Symptom‑Tracking Apps on Reporting](https://pubmed.ncbi.nlm.nih.gov/32790051/)). For practical routine management, keep dose history, symptom logs, injection sites, and weight progress in one organized place. Pepio helps you keep those records together so you can spot trends before a clinician visit. To try Pepio, download the iOS app from the App Store or use the free web tools at [pepio.app](https://pepio.app) for dose calculators, trackers, and exportable timelines you can bring to clinician visits. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, dosing recommendations, or protocol recommendations. Always follow the instructions from your clinician, prescriber, pharmacist, medication label, or care team. Next steps: download the Pepio iOS app from the App Store or use the free web tools at [pepio.app](https://pepio.app) to log your last shot, note any symptoms since that dose, and export timelines or PDFs to share with your clinician.